Kaposi's sarcoma natural history

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2] Amandeep Singh M.D.[3] Huda A. Karman, M.D.

Kaposi's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kaposi's sarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kaposi's sarcoma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kaposi's sarcoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kaposi's sarcoma natural history

CDC on Kaposi's sarcoma natural history

Kaposi's sarcoma natural history in the news

Blogs on Kaposi's sarcoma natural history

Directions to Hospitals Treating Kaposi's sarcoma

Risk calculators and risk factors for Kaposi's sarcoma natural history

Overview

The prognosis of Kaposi's sarcoma (KS) depends on its histological type, whether the cancer has spread, and the general health status of the patient. When stratified by age, the 5-year relative survival of patients with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of age respectively.

Natural History

Kaposi's sarcoma-associated herpesvirus (KSHV) infection does not always lead to KS; it is still unclear what other factors may be required, such as preexisting immune system damage, or a specific interaction with HIV or other viruses. However, research in Africa has shown that even in the absence of HIV/AIDS, KS is more common in men than women although KSHV infection is equal between both sexes. This suggests that sex hormones may either protect from or predispose to KS in persons infected with the virus. Growth can range from very slow to explosively fast, and be associated with significant mortality and morbidity.[1]

Prognosis

The prognosis of Kaposi's sarcoma depends on the following:

5-Year Survival

  • Between 2004 and 2010, the 5-year relative survival of patients with Kaposi sarcoma was 72%.[1]
  • When stratified by age, the 5-year relative survival of patients with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of age respectively.[1]

References

  1. 1.0 1.1 1.2 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.


Template:WH Template:WS